Relief Therapeutics’ Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering PKU GOLIKE®

Latest News

Stay up to date on Relief activities

Corporate News

Archive

Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations

13 December 2024 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa

11 November 2024 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger

4 November 2024 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE

29 October 2024 | non-Ad Hoc

Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents

25 October 2024 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment

21 October 2024 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa

8 October 2024 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria

4 October 2024 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces $2 Million Milestone Under Royalty Sales Agreement

23 September 2024 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024

18 September 2024 | non-Ad Hoc

Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024

2 September 2024 | non-Ad Hoc

Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update

30 August 2024 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Secures up to $11 Million from Royalty Sales

5 August 2024 | Ad Hoc Announcement pursuant to Art. 53 LR

RELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary General Meeting

26 April 2024 | non-Ad Hoc

Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

1 September 2023 | non-Ad Hoc

Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE® in the U.S. with Pentec Health

19 July 2023 | non-Ad Hoc

Relief Therapeutics Announces Swissmedic Approval and Operation of New Good Manufacturing Practice-Compliant Laboratory

15 May 2023 | non-Ad Hoc

Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares

3 May 2023 | non-Ad Hoc

Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders

28 April 2023 | non-Ad Hoc

Relief Therapeutics Announces Availability of New PKU GOLIKE BARs in Europe

16 March 2023 | non-Ad Hoc

Company

Pipeline

Investor Relations

News and Events

© Relief Therapeutics